Last reviewed · How we verify
Platelet Rich Plasma (PRP)
Platelet Rich Plasma (PRP) concentrates autologous platelets and growth factors to promote tissue repair and reduce inflammation at the site of injection.
Platelet Rich Plasma (PRP) concentrates autologous platelets and growth factors to promote tissue repair and reduce inflammation at the site of injection. Used for Osteoarthritis (knee, shoulder, hip), Tendinopathy and ligament injuries, Muscle strains and soft tissue injuries.
At a glance
| Generic name | Platelet Rich Plasma (PRP) |
|---|---|
| Also known as | The device Angel cPRP System will be used to make (Leukocyte-rich or -poor) PRP injections, PRP intervention, autologous PRP |
| Sponsor | Aspetar |
| Drug class | Autologous cell therapy / Regenerative medicine |
| Modality | Biologic |
| Therapeutic area | Orthopedics / Sports Medicine / Regenerative Medicine |
| Phase | FDA-approved |
Mechanism of action
PRP is prepared by centrifuging the patient's own blood to isolate a high concentration of platelets, which contain numerous growth factors (PDGF, VEGF, FGF, TGF-β) and cytokines. When injected into damaged tissue, these bioactive molecules stimulate cell proliferation, angiogenesis, and tissue regeneration while modulating the inflammatory response to accelerate healing.
Approved indications
- Osteoarthritis (knee, shoulder, hip)
- Tendinopathy and ligament injuries
- Muscle strains and soft tissue injuries
- Cartilage defects
Common side effects
- Injection site pain or discomfort
- Temporary swelling or inflammation
- Infection (rare)
Key clinical trials
- PRP Injection Into the Sacroiliac Joint After Ipsilateral THA: Effects on Early Recovery and Function (SIJ-THA Randomized Trial) (NA)
- Thumb Base Osteoarthritis: Ultrasound-guided Platelet-rich Plasma Versus Placebo Injection (PHASE2)
- PRP as Adjuvant Treatment to CTR for Severe CTS Tunnel Syndrome (NA)
- Identification of Responders to Platelet-Rich Plasma (PRP) Injections in Lateral Elbow Epicondylalgia
- Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage. (PHASE2)
- Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases (PHASE1, PHASE2)
- Pilot Exploration of Platelet Characterization of Platelet Rich Plasma Created by Two Different Systems (PHASE4)
- Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Platelet Rich Plasma (PRP) CI brief — competitive landscape report
- Platelet Rich Plasma (PRP) updates RSS · CI watch RSS
- Aspetar portfolio CI